Reported positive preliminary data from NKX101 Phase 1 study in patients with relapsed / refractory AML and NKX019 Phase 1 study in patients with relapsed / refractory NHL, validating the company’s platform for engineered CAR NK cell therapy candidates.

Additional NKX101 and NKX019 clinical data expected by year-end 2022, including safety and activity data for newly enrolled patients at higher dose monotherapy regimen and extended durability follow-up for previously reported patient responses.

Nkarta plans to present additional clinical data in the second half of 2022 from its ongoing dose escalation monotherapy clinical trials of NKX101 and NKX019.

In April 2022, Nkarta received approximately $215.6 million in net proceeds from a public offering of its common stock.